Skip to main content

Advertisement

Table 1 Characteristics of 14 included studies

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Study Publication year Country Study period Research subjects Study design Data resource Pazopanib No. Sunitinib No. Median age (y) Pre-treatment Median FU(m) SQ
Motzerb [7] 2013 USA 2008.8–2011.9 mRCC RCT, phase III 14 countries in USA, Europe, Australia and Asia 557 553 61/62 NPT; RDT 20/20 4
Powles [8] 2012 UK 2008–2011 clear cell mRCC RCT, phase II Multi-institution in UK 34 43 67/73 No treatment NA 3
Lalani [9] 2017 Canada 2011.1–2015.11 clear cell mRCC RS Canadian Kidney Cancer Information System database 93 577 65/64 NPT NA 7
Kim [13] 2016 Korea NA mRCC with poor risk features RS Asan Medical Center 72 100 60/57 IMT; NPT 14.2/14.2 8
Byfield [14] 2015 USA 2009.10–2012.7 aRCC RS Optum Research Database and IMPACT National Benchmarking Database 84 84 63/61.5 RDT; NPT 6.0/6.0 7
Pal [15] 2017 USA 1993.1–2012.12. aRCC RS The Surveillance, Epidemiology and End Results 89 545 68.9/68.1a NPT NA 8
Santoni [16] 2015 Italy 2005.1–2013.7 late-relapse clear-cell mRCC RS 21 Italian centers 21 190 NA RN 58.8/58.8 8
Vogelzang [17] 2017 USA 2006.1–2014.12 aRCC RS The 100% Medicare database and Part D 522 522 74/74.5 NA 15.7/15.7 9
Hansenb [18] 2015 USA 2008.8–2011.9 mRCC RCT, phase III 14 countries in USA, Europe, Australia and Asia 450 448 NA NPT; RDT 20.0/20.0 4
Racsa [19] 2015 USA 2009.11–2012.1 aRCC RS claims data 90 193 67.9/68.2a NA 12.0/12.0 7
Bianconi [20] 2016 Italy NA mRCC RS NA 19 78 68/64 renal surgery NA 7
Escudier [21] 2014 France NA mRCC RCT, phase IIIb NA 86 82 64/62 NPT; RDT NA 4
Ruiz-Morales [22] 2016 Canada 2005.1–2015.5 clear cell mRCC RS 29 cancer centers in Canada, USA, Australia and so on 919 6519 65/62 NPT; IMT NA 8
Kucharczyk [23] 2017 USA 2006.11.-2013.11 late-relapse clear cell mRCC RS A Single Institution in USA 11 4 NA NPT 38.3/38.3 6
  1. Abbreviations: mRCC: metastatic renal cell carcinoma, aRCC: advanced renal cell carcinoma, NPT: nephrectomy, RDT: radiotherapy, IMT: immunotherapy, RN: radical nephrectomy, RS: retrospective study, RCT: randomized controlled trial, NA: not available, SQ: score (RCT quality according to the Jadad scale and retrospective study quality according to the Newcastle-Ottawa scale)
  2. a Mean;
  3. b Two studies stemmed from one RCT with different aspects of results: one reported anti-tumor efficacy and toxicity; the other reported economic data